Multiple Sclerosis Society of Canada   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Toronto Canada (1948)

Organization Overview

First Clinical Trial
2006
NCT00644904
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Multiple Sclerosis Society of Canada

Active Ingredients

Drugs in Phase 3 Trials (2)

cannabis (1 trial)

minocycline (minocin) (1 trial)

Drugs in Phase 2 Trials (2)

quetiapine (seroquel) (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Recurrence (Phase 3)

Sclerosis (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4